Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Position Lessened by JPMorgan Chase & Co.

JPMorgan Chase & Co. decreased its stake in Capricor Therapeutics Inc (NASDAQ:CAPR) by 70.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,680 shares of the biotechnology company’s stock after selling 39,519 shares during the quarter. JPMorgan Chase & Co.’s holdings in Capricor Therapeutics were worth $230,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of CAPR. Vanguard Group Inc. boosted its position in Capricor Therapeutics by 44.4% during the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock valued at $31,420,000 after purchasing an additional 700,243 shares during the last quarter. Black Diamond Financial LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter valued at about $3,833,000. Swiss National Bank bought a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $930,000. Charles Schwab Investment Management Inc. increased its holdings in Capricor Therapeutics by 51.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 37,868 shares during the last quarter. Finally, Oppenheimer & Co. Inc. raised its position in Capricor Therapeutics by 52.4% during the fourth quarter. Oppenheimer & Co. Inc. now owns 104,231 shares of the biotechnology company’s stock valued at $1,438,000 after acquiring an additional 35,823 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $11.86 on Friday. Capricor Therapeutics Inc has a 52-week low of $3.52 and a 52-week high of $23.40. The stock has a fifty day moving average price of $11.84 and a two-hundred day moving average price of $14.61. The firm has a market capitalization of $541.73 million, a P/E ratio of -11.19 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. On average, equities research analysts predict that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CAPR has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.